Company news

Share this article:

Coley Pharmaceutical Group will receive $5 million from Dynavax Technologies Corporation in return for rights to market Coley's hepatitis B vaccine Heplisav. The vaccine is currently in Phase III clinical trials and Coley expects to submit it to the FDA next year. Coley is eligible for an additional $5 million payment upon US approval of the vaccine.

Advancis Pharmaceutical Corporation has changed its name to MiddleBrook Pharmaceuticals. The name change was completed pursuant to the company's jointly submitted Permanent Injunction and Order with Sanofi-Aventis of October 27, 2006, whereby the company agreed to cease using the Advancis name by June 30, 2007. In conjunction with the new name, the company has changed its NASDAQ trading symbol to MBRK, effective the start of trading on June 29.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.